LIGAND PHARMACEUTICALS INCORPORATED — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4a040647-8ad5-4cd9-aec2-d3797e63cec5/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $124.5M | 2025-01-01 – 2025-12-31 | evidence 0000886163-26-000006 |
| FY 2024 | $-4.0M | 2024-01-01 – 2024-12-31 | evidence 0000886163-25-000012 |
| FY 2023 | $52.2M | 2023-01-01 – 2023-12-31 | evidence 0000886163-24-000009 |
| FY 2022 | $-33.4M | 2022-01-01 – 2022-12-31 | evidence 0000886163-23-000007 |
| FY 2021 | $57.1M | 2021-01-01 – 2021-12-31 | evidence 0000886163-22-000030 |
| FY 2020 | $-3.0M | 2020-01-01 – 2020-12-31 | evidence 0000886163-21-000050 |
| FY 2019 | $629.3M | 2019-01-01 – 2019-12-31 | evidence 0000886163-20-000025 |
| FY 2018 | $143.3M | 2018-01-01 – 2018-12-31 | evidence 0000886163-19-000041 |
| FY 2017 | $12.6M | 2017-01-01 – 2017-12-31 | evidence 0000886163-18-000030 |
| FY 2016 | $-1.6M | 2016-01-01 – 2016-12-31 | evidence 0000886163-17-000021 |
| FY 2015 | $229.8M | 2015-01-01 – 2015-12-31 | evidence 0000886163-16-000239 |
| FY 2014 | $12.0M | 2014-01-01 – 2014-12-31 | evidence 0000886163-15-000028 |
| FY 2013 | $-527.0k | 2013-01-01 – 2013-12-31 | evidence 0000886163-14-000119 |
| FY 2012 | $9.7M | 2012-01-01 – 2012-12-31 | evidence 0000886163-14-000119 |
| FY 2011 | $9.7M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-470008 |
| FY 2010 | $-10.4M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-075655 |
| FY 2009 | $-1.9M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-075655 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
LIGAND PHARMACEUTICALS INCORPORATED — all facts · Revenue · Operating Income